I'm LongbridgeAI, I can summarize articles.AlloVir (NASDAQ:ALVR) shares rose 10.7% during trading, reaching a high of $10.27 before closing at $10.02. The trading volume increased by 405% compared to the average daily volume. AlloVir is a clinical-stage biopharmaceutical company focused on developing T-cell immunotherapies for viral infections in immunocompromised patients. Despite the stock's rise, analysts currently rate it as a Hold, suggesting there may be better investment opportunities available.
AlloVir, Inc. (NASDAQ:ALVR - Get Free Report)'s stock price rose 10.7% during trading on Wednesday . The company traded as high as $10.27 and last traded at $10.02. Approximately 79,259 shares traded hands during mid-day trading, an increase of 405% from the average daily volume of 15,685 shares. The stock had previously closed at $9.05.
AlloVir Price Performance
- MarketBeat Week in Review – 7/10 - 7/14
The stock's 50 day simple moving average is $8.83 and its 200-day simple moving average is $6.03. The stock has a market capitalization of $50.53 million, a price-to-earnings ratio of -0.50 and a beta of 0.63.
About AlloVir
(Get Free Report)AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company's proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
- Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
AlloVir's pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Recommended Stories
- Five stocks we like better than AlloVir
- Is THIS the Next Big Money Rush?
- Wall Street Legend Names #1 Stock of 2026 Live On-Camera
- ISPC: From Small Cap to Life Sciences Market Disruptor!
- The Crash Has Already Started (Most Just Don’t See It Yet)
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in AlloVir Right Now?
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here